8-K: Palisade Bio Secures $3M Investment and Clinical Partner

Palisade Bio has entered into a master services agreement with Iterative Health and raised $3 million through a private placement of common stock to support its PALI-2108 Phase 2 study.

Summary

• Palisade Bio entered into a master services agreement with Iterative Health to accelerate patient enrollment for the upcoming Phase 2 study of PALI-2108 for Ulcerative Colitis.
• The company completed a private placement of 1,536,885 shares of common stock to an affiliate of Iterative Health.
• The total gross proceeds from the stock issuance amounted to $3.0 million.
• The shares were priced at $1.952 per share, based on the five-day average closing price on the Nasdaq prior to the March 27, 2026 closing date.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development as it provides necessary capital and operational support for a key clinical asset without the need for a dilutive public market offering.

Positives

• Secured $3 million in capital to fund clinical development activities.
• Strategic partnership with Iterative Health is expected to expedite patient enrollment for the PALI-2108 Phase 2 study.
• The issuance price of $1.952 per share aligns with recent market performance, minimizing immediate dilution concerns relative to current trading levels.

Negatives

• The issuance of 1,536,885 new shares results in immediate dilution for existing shareholders.

Risks

• Clinical trial success for PALI-2108 is uncertain and subject to regulatory and scientific hurdles.
• Reliance on third-party service providers like Iterative Health introduces operational dependencies.
• The company remains subject to the broader risks and uncertainties outlined in its 2025 Annual Report on Form 10-K.

Future Outlook

The company intends to utilize the partnership with Iterative Health to accelerate the enrollment process for its upcoming Phase 2 clinical study of PALI-2108 for the treatment of moderate to severe Ulcerative Colitis.

Industry Context

StockSavvy.ai notes that small-cap biotech firms are increasingly leveraging strategic partnerships with specialized health-tech firms like Iterative Health to optimize clinical trial efficiency and reduce time-to-market, a trend driven by the high cost of patient recruitment in inflammatory bowel disease studies.

Comparison to Industry Standards

• The use of private placements to fund specific clinical milestones is a standard practice for clinical-stage biotechs to avoid the volatility of public follow-on offerings.
• Partnering with AI-driven clinical trial platforms is becoming a benchmark for companies seeking to improve enrollment speed compared to traditional CRO models.

Stakeholder Impact

• Shareholders face dilution from the issuance of 1.5 million new shares.
• Patients may benefit from potentially faster clinical trial timelines.

Next Steps

• Commencement of the Phase 2 clinical study for PALI-2108.
• Execution of patient enrollment services by Iterative Health.

Key Dates

Recommendation

The capital raise and partnership are positive operational steps, but the stock remains a high-risk clinical-stage play dependent on the success of the PALI-2108 Phase 2 trial.

Keywords

Palisade Bio, PALI-2108, Ulcerative Colitis, Iterative Health, Clinical Trial, Private Placement, Biotech